Aligos Therapeutics Inc. (NASDAQ: ALGS)
$26.3450
-0.4050 ( +1.13% ) 116.2K
Aligos Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
Market Data
Open
$26.3450
Previous close
$26.7500
Volume
116.2K
Market cap
$94.11M
Day range
$25.9910 - $27.5150
52 week range
$6.7600 - $30.0000
SEC Filings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 10-q | Quarterly Reports | 83 | Nov 06, 2024 |
| 8-k | 8K-related | 15 | Nov 06, 2024 |
| 4 | Insider transactions | 1 | Oct 10, 2024 |
| 3 | Insider transactions | 2 | Sep 26, 2024 |
| 4 | Insider transactions | 1 | Sep 06, 2024 |
| 4 | Insider transactions | 1 | Sep 06, 2024 |
| 4 | Insider transactions | 1 | Sep 06, 2024 |
| 8-k | 8K-related | 13 | Sep 05, 2024 |
| 8-k | 8K-related | 14 | Aug 19, 2024 |
| 4 | Insider transactions | 1 | Aug 09, 2024 |